MedTrace Logo

Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy

NCT01590615 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2017-04-24

No results posted yet for this study

Summary

This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.

Conditions

Interventions

DRUG

Anti-HBV nucleoside/nucleotide therapy

Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.

Sponsors & Collaborators

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-26
Primary Completion
2017-04-04
Completion
2017-04-04

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01590615 on ClinicalTrials.gov